Covered recipient · General Payments record
FRANCISCO A KERDEL
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$194,736.58
294 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $166,497.00 | 69 |
| Consulting Fee | $18,097.50 | 8 |
| Food and Beverage | $6,762.39 | 203 |
| Travel and Lodging | $3,148.97 | 10 |
| Education | $230.72 | 4 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
FRANCISCO A KERDEL
NPI 1144258724 · CMS profile ID 188421
Allopathic & Osteopathic Physicians / Dermatology
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1144258724?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- FRANCISCO A KERDEL, NPI 1144258724, CMS profile ID 188421. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144258724?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). FRANCISCO A KERDEL, NPI 1144258724, CMS profile ID 188421. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144258724?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- FRANCISCO A KERDEL, NPI 1144258724, CMS profile ID 188421, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1144258724?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
294 matching records · $194,736.58 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 294.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $28.89 | 11/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070879 | CMS |
| AbbVie Inc. | $112.98 | 11/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070883 | CMS |
| AbbVie Inc. | $4.69 | 11/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070887 | CMS |
| PFIZER INC. | $2.83 | 11/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833288021 | CMS |
| GENZYME CORPORATION | $2,112.00 | 11/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843496025 | CMS |
| Novartis Pharmaceuticals Corporation | $20.28 | 11/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812746899 | CMS |
| AbbVie Inc. | $94.72 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070871 | CMS |
| UCB, Inc. | $16.82 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807417777 | CMS |
| Janssen Scientific Affairs, LLC | $3,038.00 | 10/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787919847 | CMS |
| Amgen Inc. | $3,738.00 | 10/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826337411 | CMS |
| Incyte Corporation | $24.57 | 10/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855651013 | CMS |
| Janssen Scientific Affairs, LLC | $124.52 | 10/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787919845 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $2.21 | 10/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849552605 | CMS |
| AbbVie Inc. | $27.51 | 10/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070867 | CMS |
| LEO Pharma Inc. | $23.04 | 10/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842213599 | CMS |
| Janssen Scientific Affairs, LLC | $3,038.00 | 10/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787919837 | CMS |
| Janssen Scientific Affairs, LLC | $3,038.00 | 10/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787919843 | CMS |
| AbbVie Inc. | $28.71 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070863 | CMS |
| Janssen Scientific Affairs, LLC | $124.52 | 10/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787919839 | CMS |
| Janssen Scientific Affairs, LLC | $396.90 | 10/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787919841 | CMS |
| Lilly USA, LLC | $4,900.00 | 10/12/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819074091 | CMS |
| Helsinn Therapeutics (U.S.), Inc. | $21.06 | 10/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819746629 | CMS |
| Janssen Biotech, Inc. | $6.47 | 10/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787919773 | CMS |
| GENZYME CORPORATION | $17.96 | 10/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843495991 | CMS |
| AbbVie Inc. | $24.89 | 10/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070859 | CMS |
| AbbVie Inc. | $18.89 | 10/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070855 | CMS |
| Janssen Scientific Affairs, LLC | $124.52 | 09/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787919835 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $20.36 | 09/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851881395 | CMS |
| Amgen Inc. | $125.00 | 09/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826337415 | CMS |
| Kyowa Kirin, Inc. | $112.17 | 09/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852987319 | CMS |
| PFIZER INC. | $16.32 | 09/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832916887 | CMS |
| AbbVie Inc. | $3,000.00 | 09/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070851 | CMS |
| AbbVie Inc. | $82.25 | 09/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070845 | CMS |
| AbbVie Inc. | $26.62 | 09/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070847 | CMS |
| AbbVie Inc. | $28.41 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070840 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $18.86 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849552599 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $5.29 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849552601 | CMS |
| UCB, Inc. | $87.60 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807405737 | CMS |
| Lilly USA, LLC | $17.66 | 09/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819087201 | CMS |
| Lilly USA, LLC | $26.20 | 09/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819155767 | CMS |
| PFIZER INC. | $20.28 | 09/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832855095 | CMS |
| Novartis Pharmaceuticals Corporation | $22.30 | 09/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812746897 | CMS |
| AbbVie Inc. | $28.84 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070836 | CMS |
| LEO Pharma Inc. | $21.15 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842213591 | CMS |
| AbbVie Inc. | $3,000.00 | 08/31/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070831 | CMS |
| Amgen Inc. | $33.60 | 08/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826337407 | CMS |
| UCB, Inc. | $1,600.00 | 08/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807322411 | CMS |
| UCB, Inc. | $28.56 | 08/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807405923 | CMS |
| AbbVie Inc. | $71.82 | 08/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795070827 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,480.00 | 08/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763515472 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $336,886.17 | 74 |
| PY2024 | Recipient | $199,350.00 | 1 |
| PY2024 | Principal investigator | $649,461.93 | 118 |
| PY2023 | Recipient | $4,200.00 | 1 |
| PY2023 | Principal investigator | $362,191.95 | 50 |
| PY2022 | Recipient | $38.00 | 1 |
| PY2022 | Principal investigator | $212,855.61 | 51 |
| PY2021 | Recipient | $66,875.00 | 1 |
| PY2021 | Principal investigator | $309,055.10 | 69 |
| PY2020 | Recipient | $592,927.15 | 7 |
| PY2020 | Principal investigator | $668,650.57 | 78 |
| PY2019 | Recipient | $27,841.04 | 7 |
| PY2019 | Principal investigator | $492,794.35 | 62 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
74 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $665.04 | 12/31/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC DERMATOLOGY CENTER | A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202534383 |
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC DERMATOLOGY CENTER | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202534385 |
| Principal investigator 1 | ABBVIE INC. | $3,537.36 | 12/31/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC DERMATOLOGY CENTER | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202534387 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $16,159.50 | 12/18/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246432024 |
| Principal investigator 1 | ABBVIE INC. | $1,582.10 | 12/04/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202527288 |
| Principal investigator 1 | ABBVIE INC. | $2,408.00 | 12/04/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202527290 |
| Principal investigator 1 | ABBVIE INC. | $3,536.25 | 12/04/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202527292 |
| Principal investigator 1 | Incyte Corporation | $438.60 | 12/04/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240535182 |
| Principal investigator 1 | Incyte Corporation | $718.50 | 12/04/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240535186 |
| Principal investigator 1 | Eli Lilly and Company | $19,935.00 | 12/01/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION | Not supplied | No dispute reported | 06/30/2026 | 1187883280 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,978.02 | 12/01/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289041 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $24,822.54 | 11/15/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190302047 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,295.05 | 11/13/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246432021 |
| Principal investigator 1 | ABBVIE INC. | $2,730.40 | 11/05/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202522171 |
| Principal investigator 1 | ABBVIE INC. | $1,820.00 | 11/05/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202522173 |
| Principal investigator 1 | ABBVIE INC. | $9,500.00 | 11/05/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC DERMATOLOGY CENTER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522175 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,705.44 | 10/22/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287269 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $10,267.20 | 10/13/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis | No dispute reported | 06/30/2026 | 1246432008 |
| Principal investigator 1 | ABBVIE INC. | $1,352.00 | 10/09/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202516299 |
| Principal investigator 1 | ABBVIE INC. | $5,396.25 | 10/09/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202516301 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $10,828.86 | 10/09/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246432016 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,197.47 | 09/26/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285999 |
| Principal investigator 1 | ABBVIE INC. | $7,518.75 | 09/03/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202507499 |
| Principal investigator 1 | ABBVIE INC. | $1,313.00 | 09/03/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202507501 |
| Principal investigator 1 | ABBVIE INC. | $1,410.50 | 09/03/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202508184 |
| Principal investigator 1 | Janssen Research & Development, LLC | $268.00 | 08/19/2025 | Non-covered Recipient Entity Fl Acdmc Centers Rsrch and Educ Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175189003 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,993.00 | 08/19/2025 | Non-covered Recipient Entity Fl Acdmc Centers Rsrch and Educ Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175189119 |
| Principal investigator 1 | Incyte Corporation | $318.60 | 08/14/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240535169 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $26,025.44 | 08/13/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246432013 |
| Principal investigator 1 | ABBVIE INC. | $1,352.00 | 08/06/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202503261 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,978.02 | 08/01/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283693 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,645.94 | 08/01/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283695 |
| Principal investigator 1 | ABBVIE INC. | $8,352.50 | 07/02/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202494855 |
| Principal investigator 1 | ABBVIE INC. | $1,410.50 | 07/02/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202494857 |
| Principal investigator 1 | ABBVIE INC. | $2,717.20 | 07/02/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202494859 |
| Principal investigator 1 | Incyte Corporation | $2,016.00 | 06/24/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240535165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,021.00 | 06/13/2025 | Non-covered Recipient Entity Fl Acdmc Centers Rsrch and Educ Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175189079 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,958.28 | 06/13/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223281250 |
| Principal investigator 1 | Incyte Corporation | $2,366.00 | 06/05/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240535160 |
| Principal investigator 1 | ABBVIE INC. | $6,551.25 | 06/03/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202488135 |
| Principal investigator 1 | ABBVIE INC. | $1,714.70 | 06/03/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202488233 |
| Principal investigator 1 | ABBVIE INC. | $1,293.50 | 06/03/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202488235 |
| Principal investigator 1 | ABBVIE INC. | $305.70 | 06/03/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202488237 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $204.95 | 05/27/2025 | Non-covered Recipient Entity Florida Academic Dermatology Center | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235997369 |
| Principal investigator 1 | Incyte Corporation | $318.60 | 05/08/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240535178 |
| Principal investigator 1 | ABBVIE INC. | $2,730.40 | 05/07/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202483127 |
| Principal investigator 1 | ABBVIE INC. | $5,558.75 | 05/06/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202481713 |
| Principal investigator 1 | Incyte Corporation | $1,447.30 | 04/15/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240535173 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,555.00 | 04/11/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277832 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,179.80 | 04/04/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis | No dispute reported | 06/30/2026 | 1246432003 |
| Principal investigator 1 | ABBVIE INC. | $7,466.25 | 04/03/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202473955 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,122.00 | 03/21/2025 | Non-covered Recipient Entity Fl Acdmc Derm Ctrs | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175189134 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,215.46 | 03/21/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276927 |
| Principal investigator 1 | ABBVIE INC. | $4,462.50 | 03/07/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202459301 |
| Principal investigator 1 | ABBVIE INC. | $3,798.60 | 03/07/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202459305 |
| Principal investigator 1 | ABBVIE INC. | $1,608.10 | 03/07/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202459422 |
| Principal investigator 1 | ABBVIE INC. | $1,943.50 | 03/07/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202459490 |
| Principal investigator 1 | ABBVIE INC. | $1,174.40 | 03/06/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202456597 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,169.00 | 03/03/2025 | Non-covered Recipient Entity Fl Acdmc Derm Ctrs | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175189141 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,310.00 | 02/27/2025 | Non-covered Recipient Entity Fl Acdmc Centers Rsrch and Educ Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189095 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,000.00 | 02/26/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275591 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,642.00 | 02/25/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1190301635 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $32,323.00 | 02/12/2025 | Non-covered Recipient Entity Florida Academic Dermatology Center | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235997367 |
| Principal investigator 1 | ABBVIE INC. | $1,266.20 | 02/06/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202446787 |
| Principal investigator 1 | ABBVIE INC. | $1,849.90 | 02/06/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202446861 |
| Principal investigator 1 | ABBVIE INC. | $2,483.75 | 02/06/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202446866 |
| Principal investigator 1 | ABBVIE INC. | $1,293.50 | 02/06/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202446887 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 01/27/2025 | Non-covered Recipient Entity Fl Acdmc Centers Rsrch and Educ Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189187 |
| Principal investigator 1 | Incyte Corporation | $1,818.00 | 01/17/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240535191 |
| Principal investigator 1 | Incyte Corporation | $2,129.40 | 01/07/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240535195 |
| Principal investigator 1 | ABBVIE INC. | $1,266.20 | 01/02/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202433457 |
| Principal investigator 1 | ABBVIE INC. | $1,574.30 | 01/02/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202433462 |
| Principal investigator 1 | ABBVIE INC. | $305.70 | 01/02/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202433489 |
| Principal investigator 1 | ABBVIE INC. | $3,568.75 | 01/02/2025 | Non-covered Recipient Entity FLORIDA ACADEMIC CENTERS | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202433517 |